Reviva Pharmaceuticals Holdings, Inc. (RVPH) 10-Year Financial Performance & Capital Metrics

RVPH • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutReviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.Show more

Revenue $0
EBITDA -$30M +24.4%
Net Income -$30M +23.8%
EPS (Diluted) -0.90 +45.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -916.17% -110.4%
ROIC -
Debt/Equity 0.56
Interest Coverage -1665.07

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 39.3% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 14.3x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM23.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM50.27%

ROCE

10Y Avg-366.16%

5Y Avg-439.1%

3Y Avg-450.78%

Latest-829.38%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Feb 2019	Feb 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	724.74K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	-724.74K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	1%	-	-	-
Operating Expenses+	1.12M	376.86K	2.43M	10.1M	24.31M	39.5M	30.8M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	175.58K	181.12K	2.14M	5.25M	5.36M	8.08M	7.89M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	946.3K	195.74K	295.15K	4.85M	18.95M	31.42M	22.91M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-1.12M	-376.86K	-2.43M	-10.1M	-24.31M	-39.5M	-30.8M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	0.66%	-5.46%	-3.15%	-1.41%	-0.63%	0.22%
EBITDA+	-1.12M	-376.01K	-2.33M	-9.87M	-24.11M	-39.5M	-29.88M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	0.66%	-5.19%	-3.24%	-1.44%	-0.64%	0.24%
D&A (Non-Cash Add-back)	1.02K	846	105.77K	236.56K	194.71K	0	0
EBIT	-1.12M	-376.86K	-2.43M	0	-24.31M	-39.24M	-29.88M
Net Interest Income+	-557.67K	-469.17K	-1.35M	-2.41K	0	0	342.87K
Interest Income	0	201	105.18K	0	182.8K	0	361.37K
Interest Expense	557.67K	469.37K	1.45M	2.41K	182.8K	0	18.5K
Other Income/Expense	-557.67K	-469.17K	-1.35M	1.59M	-11.91K	39.5M	899.6K
Pretax Income+	-1.68M	-846.03K	-3.78M	-8.52M	-24.32M	-39.24M	-29.9M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	800	800	800	6K	20.78K	16.95K	19.51K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.68M	-846.83K	-3.78M	-8.52M	-24.34M	-39.26M	-29.92M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	0.5%	-3.47%	-1.25%	-1.86%	-0.61%	0.24%
Net Income (Continuing)	-1.68M	-846.83K	-3.78M	-8.52M	-24.34M	-39.26M	-29.92M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	0.28	-0.31	-1.24	-0.58	-1.45	-1.65	-0.90
EPS Growth %	-	-2.1%	-2.99%	0.53%	-1.51%	-0.14%	0.45%
EPS (Basic)	0.28	-0.31	-1.24	-0.58	-1.45	-1.65	-0.90
Diluted Shares Outstanding	2.04M	2.77M	3.06M	14.79M	19.52M	23.8M	33.15M
Basic Shares Outstanding	2.04M	2.77M	3.06M	14.79M	19.52M	23.8M	33.15M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Feb 2019	Feb 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	65.24M	193	8.76M	31.4M	18.92M	23.7M	14.68M
Cash & Short-Term Investments	65.24M	193	8.76M	29.69M	18.52M	23.37M	13.48M
Cash Only	0	193	8.76M	29.69M	18.52M	23.37M	13.48M
Short-Term Investments	65.24M	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	69.58K	1.72M	403.82K	332.93K	666.43K
Total Non-Current Assets+	0	2.41K	1.82K	0	0	0	819.72K
Property, Plant & Equipment	0	591	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	1.82K	1.82K	0	0	0	819.72K
Total Assets+	65.24M	2.6K	8.76M	31.4M	18.92M	23.7M	15.5M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	-1%	3369.11%	2.58%	-0.4%	0.25%	-0.35%
Total Current Liabilities+	0	6.81M	1.33M	2.34M	6.04M	17.18M	14.6M
Accounts Payable	0	224.54K	1.01M	509.58K	3.52M	3.85M	6.28M
Days Payables Outstanding	-	-	507.68	-	-	-	-
Short-Term Debt	0	3.77M	0	0	0	0	458.15K
Deferred Revenue (Current)	0	1000K	0	0	0	0	0
Other Current Liabilities	0	-123.02K	-683.35K	1.33M	-1M	400.49K	635.59K
Current Ratio	-	0.00x	6.57x	13.39x	3.13x	1.38x	1.01x
Quick Ratio	-	0.00x	6.57x	13.39x	3.13x	1.38x	1.01x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	2.96M	372.73K	567.44K	806.65K	89.01K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	2.96M	372.73K	567.44K	806.65K	89.01K
Total Liabilities	6.09M	6.81M	1.33M	2.72M	6.61M	17.98M	14.69M
Total Debt+	0	3.77M	0	0	0	0	458.15K
Net Debt	0	3.76M	-8.76M	-29.69M	-18.52M	-23.37M	-13.02M
Debt / Equity	-	-	-	-	-	-	0.56x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-2.01x	-0.80x	-1.68x	-4185.80x	-132.97x	-	-1665.07x
Total Equity+	0	-6.81M	7.43M	28.69M	12.32M	5.72M	812.57K
Equity Growth %	-	-	2.09%	2.86%	-0.57%	-0.54%	-0.86%
Book Value per Share	-	-2.46	2.43	1.94	0.63	0.24	0.02
Total Shareholders' Equity	0	-6.81M	7.43M	28.69M	12.32M	5.72M	812.57K
Common Stock	0	618	923	1.44K	2.04K	2.79K	4.66K
Retained Earnings	0	-54.53M	-58.31M	-66.83M	-91.17M	-134.35M	-164.27M
Treasury Stock	0	-	-	-	-	0	0
Accumulated OCI	0	-54.53M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Feb 2019	Feb 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.07M	-218.44K	-3.73M	-10.67M	-18.96M	-28.32M	-33.54M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	0.8%	-16.06%	-1.86%	-0.78%	-0.49%	-0.18%
Net Income	-1.68M	-846.83K	-3.78M	-8.52M	-24.34M	-39.26M	-29.92M
Depreciation & Amortization	17.72K	645	591	0	0	0	0
Stock-Based Compensation	21.05K	0	0	106.71K	176.74K	3.41M	1.63M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	28.24K	-6.41K	2.39M	-1.55M	194.71K	239.22K	-717.64K
Working Capital Changes	541.98K	634.15K	-2.33M	-702.17K	5.01M	7.28M	-4.54M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	0	158.17K	775.1K	-498.46K	3.01M	328.84K	2.29M
Cash from Investing+	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	175K	100K	12.83M	31.6M	7.79M	33.17M	23.65M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	175K	0	12.83M	98.48K	18.97K	5.68M	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-1.07M	-218.44K	-3.73M	-10.67M	-18.96M	-28.32M	-33.54M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	0.8%	-16.06%	-1.86%	-0.78%	-0.49%	-0.18%
FCF per Share	-0.53	-0.08	-1.22	-0.72	-0.97	-1.19	-1.01
FCF Conversion (FCF/Net Income)	0.64x	0.26x	0.98x	1.25x	0.78x	0.72x	1.12x
Interest Paid	0	-	-	-	-	30.62K	18.5K
Taxes Paid	0	-	-	-	-	19.75K	3.42K

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-1224.19%	-47.19%	-118.72%	-435.38%	-916.17%
Debt / Equity	-	-	-	-	-	-	0.56x
Interest Coverage	-2.01x	-0.80x	-1.68x	-4185.80x	-132.97x	-	-1665.07x
FCF Conversion	0.64x	0.26x	0.98x	1.25x	0.78x	0.72x	1.12x

Frequently Asked Questions

Growth & Financials

Reviva Pharmaceuticals Holdings, Inc. (RVPH) grew revenue by 0.0% over the past year. Growth has been modest.

Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported a net loss of $27.1M for fiscal year 2024.

Dividend & Returns

Reviva Pharmaceuticals Holdings, Inc. (RVPH) has a return on equity (ROE) of -916.2%. Negative ROE indicates the company is unprofitable.

Reviva Pharmaceuticals Holdings, Inc. (RVPH) had negative free cash flow of $26.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener